ASHLEE FANCHER: Open Payments
NPI 1629737002 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$976 in 50 payments from 13 companies in 2025. Trend: 2023 $80 · 2024 $642 · 2025 $976
Food & beverage: $976
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $282 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $185 |
| Globus Medical, Inc. | 4 | $106 |
| Lilly USA, LLC | 6 | $97 |
| ABBVIE INC. | 4 | $60 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Otsuka America Pharmaceutical, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 1 | $22 |
| PFIZER INC. | 1 | $21 |
Products named: CAPLYTA, AIRSUPRA, FARXIGA, Senza, MOUNJARO, REXULTI, VRAYLAR, XIFAXAN.
Industry payments across MO — which companies pay providers there.
